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INTRODUCTION
Plasmodium vivax malaria is found across a large area
of the globe and potentially affects larger number of people
than P. falciparum malaria. It is endemic across around
44 million km2, approximately a third of earthland. India
alone contributes nearly half (46%) of the global popula-
tion at risk and two thirds of those are at stable risk1. In
spite of this, most of the research and published literature
on malaria focus on P. falciparum and the P. vivax re-
mains a neglected tropical disease2. However, last few
years have witnessed a major shift in relation to research
on clinical and epidemiological behaviour of P. vivax3–4.
Firstly, there are increasing reports in literature from dif-
ferent parts of the world through different types of stud-
ies describing severe and sometime fatal malaria includ-
ing deaths by P. vivax in certain settings5–31. Reported
severe manifestations include cerebral malaria, general-
ized convulsion and status epilepticus, hepatic dysfunc-
tion and jaundice, acute lung injury, acute respiratory dis-
tress syndrome (ARDS) and pulmonary edema, acute
kidney injury, severe anaemia, severe thrombocytopenia
with or without bleeding, hypoglycemia and shock6,12,14.
Recently, the deaths due to P. vivax monoinfection have
also been established by histopathological confirmation
of autopsy specimens32–33. In some of these studies, the
diagnosis of P. vivax monoinfection was established by
polymerase chain reaction (PCR) examination thereby
negating any chance of coinfection with P.
falciparum5,6,9,12–15,17–19,28 and have undertaken exhaus-
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ABSTRACT
Background & objectives: Description of severe vivax malaria and mixed species infection requires good clinical
study. The present study was undertaken to evalute the characteristics of severe malaria patients in Bikaner,
northwest India.
Methods: This prospective study included 539 admitted adult patients of severe malaria (Plasmodium falciparum
274, P. vivax 221, and mixed infection of Pv + Pf 44). The diagnosis was confirmed by polymerase chain reaction.
The categorization of severe malaria was done strictly as per WHO criteria.
Results: The distribution of severe manifestation was similar in severe vivax, falciparum and mixed infections
except more cases of thrombocytopenia in P. vivax (p=0.030) and in mixed infection (p=0.004). The risk of
developing severe malaria was greatest in patients of mixed infection [53.01% (44/83)] in comparison to
Plasmodium falciparum malaria [49.37% (274/555), RR= 1.135; p=0.616] and P. vivax malaria [45.38% (221/
487), RR = 1.299, p=0.243]. Hepatic dysfunction was the commonest pernicious syndrome [P. falciparum 50%
(137/274), P. vivax 43.89% (97/221), and mixed infections 54.55% (24/44)]. Multiorgan dysfunction was present
in 40.26% (217/539) patients, the risk was greatest in mixed infection [90.90% (40/44)] in comparison to P.
falciparum monoinfection [37.59% (103/274), RR = 12.238; p=0.0001] or P. vivax monoinfection [33.48% (74/
221), RR = 13.25; p=0.0001]. The risk of mortality in severe malaria was 6.31% (34/539) in which mixed infection
had greater risk [9.09% (4/44)] in comparison to P. falciparum [7.30% (20/274); OR = 1.270 (CI 0.347–4.217);
p=0.757] or P. vivax [4.52% (10/221); 0R 2.110 (CI 0.527–7.826); p=0.260].
Interpretation & conclusion: Severe vivax or falciparum malaria had almost similar features and prognosis including
mortality. Risk of developing severe malaria, multiorgan dysfunction and mortality was more in patients of mixed
infection in comparison to P. falciparum or P. vivax monoinfection. A multicentric study on larger number of
patients requires further confirmation.
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tive clinical, biochemical and radiological studies to rule
out associated comorbid conditions6,12–14,17–18,28.
The second puzzling question is in relation to the clini-
cal profile of mixed (P. vivax with P. falciparum) infec-
tion. There are various reports in literature providing evi-
dence of increasing/no change7, 11 or reducing34–37 the
severity and morbidity in patients of mixed infection in
relation to P. falciparum monoinfection. However, the
diagnosis in these patients was not confirmed by PCR
examination thereby limiting the reliability of exact spe-
ciation in comparison to molecular diagnosis16–17.
The characteristics and outcome of severe malaria are
best assessed through a prospective study in an ethnically
homogenous sample and with clinical and laboratory data
sufficient to allow accurate diagnosis as well as the de-
tection of important comorbid condition17. Many of the
earlier studies in relation to the description of severe P.
vivax malaria and severe mixed infection malaria have
neither used strictly defined WHO criteria nor ruled out
associated comorbid conditions. In majority of these stud-
ies, the diagnosis was established by peripheral blood film
(PBF) examination only thereby not providing enough
strength in clinical and species diagnosis7, 10–11. Earlier,
we have carried out hospital-based prospective observa-
tional study to describe the clinical presentation of PCR
confirmed cases of severe vivax malaria in children and
adults6,9,14,18. In this prospective hospital-based observa-
tional study on adult patients of PCR diagnosed severe
malaria (P. falciparum, P. vivax and mixed infection), in
which associated comorbid conditions were ruled out by
thorough laboratory evaluation, we have carried out de-
tailed clinical, biochemical and radiological examinations
to study the complete clinical spectrum of severe illness
as described by WHO for P. falciparum malaria38 along
with thrombocytopenia as well as to study the effect of
mixed infection on morbidity and mortality.
MATERIAL & METHODS
Study site
This prospective study was carried out at the Depart-
ment of Medicine, Sardar Patel Medical College and as-
sociated group of Hospitals, Bikaner, Rajasthan, India
from January 2007 to December 2008. Bikaner is a part
of Thar Desert and is hypoendemic region for malaria.
Hospital guideline requires detailed study of PBF exami-
nation for malaria parasites for all the patients presenting
with history of fever.
Study procedures
This prospective study was conducted on admitted
adult patients of malaria in whom the diagnosis was done
by PBF and rapid diagnostic test (RDT). After thorough
clinical and laboratory examination, the categorization of
severe malaria and treatment was done according to WHO
guidelines38. The final confirmation of species diagnosis
was done by PCR examination. The study plan was ap-
proved by the hospital research committee and a written
consent of patients/relatives was mandatory. Further, de-
tails of all the patients were collected on a study proforma
(used in our earlier studies also)6,12,14 by a study team of
researchers.
Selection criteria
Adult patients of malaria with severe manifestations
and evidence of asexual phase of malaria parasite in PBF
and/or positive RDT along with positive PCR evidence
of malaria.
Exclusion criteria
Patients who refused to give the written consent or
had evidence of other concurrent illness were not included
in the study.
Laboratory procedures
Diagnostic methods used for detection of malaria
parasites were conventional thick and thin PBF stained
with Giemsa stain and microscopically examined under
oil immersion. The slide was considered negative when
there were no parasites in the 200 high-power field. The
RDTs were based on detection of specific Plasmodium
antigen, lactate dehydrogenase (OptiMal test; Diamed AG,
Cressier sur Morat, Switzerland) and histidine-rich pro-
tein-2 (Falcivax test; Zephyr Biomedical System, Goa,
India). Final categorization of P. vivax, P. falciparum or
mixed infection was done by PCR examination in all the
patients having severe manifestations. Other laboratory
investigations in all the patients of severe malaria included
complete blood count, platelet count, bleeding time, clot-
ting time, blood glucose, blood urea, serum creatinine,
serum bilirubin (conjugated and unconjugated), serum
aspartate aminotransferase (AST), serum alanine ami-
notransferase (ALT), serum alkaline phosphatase, com-
plete urine analysis, electrocardiogram, and appropriate
blood test to rule out typhoid fever (typhi dot test), lep-
tospirosis, and dengue infection (differential detection of
IgG and IgM antibodies) and HIV. Depending upon the
clinical situation, other tests included skigram chest,
serum electrolytes, and arterial blood gas analysis for
acute respiratory distress syndrome (ARDS); fundus
examination, cerebrospinal fluid (CSF) examination,
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electroencephalography (EEG) in patients having repeated
convulsion and cerebral malaria (CM); ultrasonography
of whole abdomen and specific test for hepatitis B and C
in hepatic dysfunction and jaundice and glucose-6-phos-
phate dehydrogenase (G6PD) enzyme level (kinetic
method: G-SIX Kit, Crest Biosystems, Goa) for hemoly-
sis. Blood culture was taken on brain-heart infusion broth
in every patient who was having continuous high grade
fever >101°F for > 24 h after admission. Parasite density
was estimated in all the patients of severe vivax malaria.
The PCR confirmation was done in all the patients hav-
ing severe manifestations with evidence of malaria on PBF
and/or RDT. The PCR studies were targeted against the
18S ribosomal RNA gene of the parasite and used one
genus specific 5′ primer and two species-specific 3′ prim-
ers in the same reaction mixture and details are described
in earlier reports6,12,14. All the clinical syndromes were
classified according to WHO38 criteria and the involve-
ment of two or more than two organs were considered as
multiorgan dysfunction (MODS). Specific antimalarial
treatment was given in the hospital according to WHO
guidelines38.
Statistical analysis
Morbidity spectrum and mortality pattern of patients
infected with P. falciparum monoinfection, P. vivax
monoinfection and mixed infection were compared and
analyzed individually with Odds ratio with 95% confi-
dence interval via SPSS version 14.0.
RESULTS
During the study period (January 2007 to December
2008), 24,703 adult patients of fever attended the hospi-
tal, of which 1155 patients had positive evidence of ma-
laria by PBF examination and/or RDT test and required
admission. Exact species diagnosis of severe malaria was
confirmed by PCR examination. A total of 32 patients
who had evidence of concomitant illness, unable to get
written consent and had problems related to confirmation
of species by PCR examination, were not included in the
study. Thus, the subsequent analysis was done in 1123
patients, that included 584 uncomplicated malaria and 539
severe malaria patients. The details of species diagnosis
along with distribution of complicated and uncomplicated
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malaria are shown in Fig. 1. The male : female ratio in
patients infected with P. falciparum, P. vivax and mixed
infection was 1.52 (335 : 220), 1.50 (291 : 194) and 2.32
(58 : 25), respectively. Although, 50.83% (274/539) of
severe malaria cases were caused by P. falciparum. The
risk of developing severe malaria was greatest in patients
of mixed infection [53.01% (44/83)] in comparison to P.
falciparum malaria [49.37% (274/555), RR = 1.135;
p=0.616] and P. vivax malaria [5.38% (221/487), RR =
1.299; p=0.243]. The details of severe manifestations in
patients with P. vivax, P. falciparum and mixed infec-
tions are shown in Table 1. The peripheral blood film of
patients of severe vivax malaria showed predominantly
trophozoites and the density of parasites was 800–68000/
mm3 (mean ± SD = 14000 ± 13285.85).
Presenting clinical features
Of 274 patients with severe P.  falciparum
monoinfection, 137 (50%) had jaundice, 115 (41.97%)
had severe anaemia (haemoglobin <5 g/dl), 86 (31.39%)
had thrombocytopenia, 36 (13.14%) had renal failure, 29
(10.58%) had cerebral malaria and 2 (0.72%) had ARDS
(Table 1). Patients with severe P. vivax monoinfection
(n=221) also had the similar phenotypic features reported
in severe P. falciparum monoinfection without having
statistical significant difference except more patients with
thrombocytopenia (p=0.030). When compared to those
with severe P. falciparum malaria, patients with
mixed infection also had similar phenotype but thromb-
ocytopenia was more common (p=0.004) (Table 1). He-
patic dysfunction was the commonest observation in ma-
laria caused by all the species [P. falciparum 50% (137/
274), P. vivax 43.89% (97/221), and mixed infections
54.55% (24/44)].
Multiorgan dysfunction
Multiorgan dysfunction (involvement of two or more
organs) was present in 40.26% (217/539) patients having
severe malaria. Although, 47.47% (103/217) of
multiorgan dysfunction was caused by P. falciparum
malaria, the risk was greatest in patients having mixed
infection [90.90% (40/44)] in comparison to either P.
falciparum monoinfection [37.59% (103/274), RR =
12.238; p=0.0001] or P. vivax monoinfection [33.48%
(74/221), RR = 13.25; p=0.0001]. Potentiality of P. vivax
malaria for causing multiorgan dysfunction was similar
to P. falciparum malaria (RR = 1.082; p=0.394). The de-
tails of different combinations in different species with
their statistical significance are given in Table 2. How-
ever, the important observation anaemia with jaundice
was more common in P. falciparum malaria in compari-
son to P. vivax malaria (p<0.007) and mixed infection.
Anaemia with thrombocytopenia was significantly more
common in mixed infection (p<0.003) and P. falciparum
(p<0.05) infection in comparison to P. vivax infection.
Anaemia with cerebral malaria was significantly more
Table 1. The distribution of pernicious syndrome (n=539) in different species
Malaria species P. falciparum P. vivax Mixed infection Comparison 95% Confidence interval (CI)
Complications (n=274) % (n=221) % (n=44) % group Odds ratio LL UL p-value
Cerebral malaria 29 10.58 21 9.50 5 11.36 Pv vs Pf 0.887 0.494 1.593 0.765
Pv vs mixed 0.819 0.300 2.219 0.781
Pf vs mixed 0.923 0.347 2.441 0.797
Anaemia 115 41.97 76 34.39 17 38.64 Pv vs Pf 0.725 0.502 1.045 0.095
Pv vs mixed 0.832 0.430 1.610 0.607
Pf vs mixed 1.149 0.602 2.189 0.743
Thrombocytopenia 86 31.39 91 41.18 24 54.55 Pv vs Pf 1.530 1.058 2.214 0.030*
Pv vs mixed 0.583 0.306 1.111 0.133
Pf vs mixed 0.381 0.201 0.722 0.004*
Jaundice 137 50 97 43.89 25 56.82 Pv vs Pf 0.782 0.548 1.116 0.205
Pv vs mixed 0.595 0.312 1.135 0.137
Pf vs mixed 0.760 0.403 1.434 0.421
Renal failure 36 13.14 21 9.50 6 13.64 Pv vs Pf 0.694 0.395 1.221 0.257
Pv vs mixed 0.665 0.258 1.705 0.415
Pf vs mixed 0.958 0.387 2.361 1
ARDS 2 0.72 2 0.90 0 0 Pv vs Pf 1.242 0.217 7.097 1
Pv vs mixed – – – –
Pf vs mixed – – – –
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common in P. vivax malaria in comparison to P.
falciparum (p<0.0002) malaria and mixed infection
(p<0.02). Anaemia with renal failure was significantly
more common in P. vivax malaria in comparison to P.
falciparum malaria (p<0.04) and mixed infection (p<0.05).
Mortality
Out of 539 patients of severe malaria admitted in the
hospital, 34 patients expired (20 P. falciparum; 10 P.
vivax; 4 mixed). There was no fatality in any patient hav-
ing single organ dysfunction. The risk of mortality in se-
vere malaria was 6.31% (34/539) in which mixed infec-
tions had greater risk [9.09% (4/44)] in comparison to
monoinfection as a whole [6.06% (30/495); OR = 1.550
(CI 0.439–4.932); p= 0.511] and either P. falciparum
monoinfection alone [7.30% (20/274); OR = 1.270 (CI
0.347–4.217); p=0.757] or P. vivax monoinfection alone
[4.52% (10/221); OR 2.110 (CI 0.527–7.826); p=0.260].
The differences were statistically not significant probably
because of smaller number of cases in mixed infection
malaria group. All the patients had severe manifestations
and multiorgan dysfunction. While analyzing the indi-
vidual severe manifestation, it was found that jaundice
was present in majority of cases [85.29% (29/34)] in all
types of malaria infections (P. falciparum = 90%, P.
vivax = 80% and mixed infection = 75%). Besides jaun-
dice, other severe manifestations associated with mortal-
ity in P. falciparum and mixed infection groups were se-
Table 2. Distribution of combination of pernicious syndrome (n=217) in different species
Malaria species P. falciparum P. vivax Mixed infection Comparison 95% Confidence interval (CI)
Complications (n=274) (n=221) (n=44) group
(n=103) % (n=74) % (n=40) % Odds ratio LL UL p-value
Anaemia + 33 32.04 10 13.51 6 15 Pv vs Pf 0.33 0.15 0.72 0.007*
Jaundice Pv vs mixed 1.129 0.378 0.579 1
Pf vs mixed 0.37 0.143 0.97 0.65
Anaemia + 39 37.86 13 17.57 18 45 Pv vs Pf 0.349 0.17 0.717 0.05*
Thrombocytopenia Pv vs mixed 3.83 1.618 9.109 0.003*
Pf vs mixed 1.342 0.641 2.81 0.55
Anaemia + 4 3.88 17 22.97 2 5 Pv vs Pf 7.38 2.36 23 0.0002*
Cerebral malaria Pv vs mixed 0.172 0.038 0.808 0.02*
Pf vs mixed 1.302 0.229 7.407 0.5
Anaemia + 9 8.74 15 20.27 2 5 Pv vs PF 2.65 1.092 6.547 0.04*
Renal failure Pv vs mixed 0.207 0.04 0.95 0.05*
Pf vs mixed 0.549 0.113 2.663 0.35
Jaundice + 35 33.98 24 32.43 16 40 Pv vs Pf 0.932 0.492 1.75 1
Thrombocytopenia Pv vs mixed 0.72 0.324 1.599 0.548
Pf vs mixed 1.295 0.61 2.749 0.631
Jaundice + 6 5.83 6 8.11 6 15 Pv vs Pf 1.426 0.441 4.11 0.7
Cerebral malaria Pv vs mixed 2 0.599 6.668 0.2
Pf vs mixed 2.85 0.861 9.445 0.07*
Jaundice + 22 21.36 8 10.81 4 10 Pv vs Pf 0.446 0.186 1.061 0.1
Renal failure Pv vs mixed 0.916 0.258 3.25 0.5
Pf vs mixed 0.409 0.131 1.273 0.18
Renal failure + 6 5.83 4 5.41 2 5 Pv vs Pf 0.925 0.251 3.39 0.5
Thrombocytopenia Pv vs mixed 0.921 0.161 5.262 0.6
Pf vs mixed 0.85 0.164 4.407 0.6
Renal failure + 4 3.88 4 5.41 2 5 Pv vs Pf 1.413 0.342 5.84 0.4
Cerebral malaria Pv vs mixed 0.921 0.161 5.262 0.6
Pf vs mixed 1.3 0.0229 7.401 0.5
Cerebral malaria + 4 3.88 3 4.05 2 5 Pv vs Pf 1.045 0.227 4.818 0.6
Thrombocytopenia Pv vs mixed 1.245 0.199 7.78 0.57
Pf vs mixed 1.302 0.229 7.4 0.53
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vere anaemia (P. falciparum = 65%, and mixed infec-
tion = 75%), renal failure (P. falciparum = 50% and mixed
infection = 50%) and thrombocytopenia (P. falciparum =
35% and mixed infection = 75%) in contrast to P. vivax
monoinfection in which other associated severe manifes-
tations were cerebral malaria (40%), renal failure (40%)
and thrombocytopenia (40%). The details of mortality and
different combinations of organ dysfunction with differ-
ent species are shown in Table 3. The differences were
not statistically significant.
DISCUSSION
Severe and complicated malaria is usually caused by
P. falciparum but it has been increasingly observed that
P. vivax malaria and mixed infection malaria can also
cause similar complication and death in occasional pa-
tient. However, most of the studies are lacking in accu-
rate malaria diagnosis by PCR and detection of
comorbidities which are likely to influence the clinical
course of illness. Moreover, no absolute severity criteria
exist for P. vivax malaria, however, WHO criteria for P.
falciparum malaria seems to be applicable and had been
used by many previous studies from India, Brazil, Papua
New Guinea, Indonesia and other parts of the world. The
reported severe manifestations included cerebral malaria,
hepatic dysfunction, renal dysfunction, severe anaemia,
ARDS, shock, pulmonary edema, haemoglobinuria, hy-
poglycemia and multiple organ involvement, along with
thrombocytopenia which has also been included in many
previous similar studies from all over the world5–31. In
this prospective hospital based clinical observational study
on adult patients of malaria, we have carried out detailed
clinical, biochemical, radiological and laboratory evalu-
ation of all the patients (P. falciparum, P. vivax and mixed
infection) to study the complete clinical spectrum of
severe illness as described by WHO for P. falciparum
malaria38 along with thrombocytopenia. The diagnosis of
all the patients was confirmed by PCR to overcome the
fallacies in the results obtained by PBF and/or RDT and
an attempt was made to be reasonably sure to rule out
possibilities of other co-morbid conditions in a scientific
manner.
This study included 1123 admitted adult patients, of
which 584 were of uncomplicated malaria and 539 were
of severe malaria. Although, 50.83% (274/539) of severe
malaria was caused by P. falciparum, the risk of devel-
oping severe malaria was greatest in patients of mixed
infections [53.01% (44/83)] in comparison to P.
falciparum malaria [49.37% (274/555)] and P. vivax ma-
laria [45.38% (221/487)]. Patients with severe vivax
monoinfection (n=221) and severe mixed infection ma-
laria (n=44)) also had the similar phenotypic features as
observed in severe P. falciparum monoinfection without
Table 3. Relation of pernicious syndrome and mortality (n=34)
Malaria species Total P. falciparum P. vivax Mixed infection Comparison 95% Confidence interval (CI)
Complications (n=34) (n=274) (n=221) (n=44) group
(n=20) % (n=10) % (n=4) % Odds ratio LL UL p-value
Jaundice 29 (85.29) 18 90 8 80 3 75 Pv vs Pf 0.444 0.052 3.738 0.407
Pv vs mixed 0.75 0.048 11.648 0.670
Pf vs mixed 0.333 0.022 4.929 0.436
Anaemia 18 (52.94) 13 65 1 10 4 100 Pv vs Pf 0.059 0.006 0.574 0.005*
Pv vs mixed – – – –
Pf vs mixed 0.359 0.075 1.714 0.181
Renal failure 16 (47.05) 10 50 4 40 2 50 Pv vs Pf 0.667 0.143 3.107 0.449
Pv vs mixed 1.5 0.145 15.461 0.594
Pf vs mixed 1 0.116 8.559 0.704
Thrombocytopenia 14 (41.18) 7 35 4 40 3 75 Pv vs Pf 1.238 0.259 5.913 0.548
Pv vs mixed 4.5 0.336 60.15 0.279
Pf vs mixed 5.571 0.484 64.08 0.177
Cerebral malaria 7 (20.59) 3 15 4 40 – – Pv vs Pf 3.78 0.648 72.01 0.143
Pv vs mixed – – – –
Pf vs mixed – – – –
ARDS 2 (5.88) 1 5 1 10 – – Pv vs Pf 2.111 0.118 37.720 0.563
Pv vs mixed – – – –
Pf vs mixed – – – –
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having statistical significant difference except thromb-
ocytopenia (Table 1). Hepatic dysfunction was the com-
monest observation in this study, as was reported earlier
in similar studies from India and Brazil6,12–14,19. The pro-
portion of patients affected with jaundice (serum
bilirubin >3 mg%) was P. falciparum 50% (137/274),
P. vivax 43.89% (97/221), and mixed infections 54.55%
(24/44). This finding is similar to the reported observa-
tions in severe P. falciparum and P. vivax malaria in this
region6,12,14. Renal dysfunction (serum creatinine >3
mg%) was present in 13.14% (36/274), 9.50% (21/221)
and 13.64% (6/44) patients having P. falciparum, P. vivax
and mixed infections, respectively. This has also been
reported frequently in the Indian subcontinent6,12,14. Ce-
rebral malaria (GCS <9) was present in 10.58% (29/274),
9.50% (21/221) and 11.36% (5/44) adults having P.
falciparum, P. vivax and mixed infections respectively.
Severe anaemia (haemoglobin <5 g/dl) was present in
41.97% (115/274), 34.39% (76/221), and 38.64% (17/
44) adults having P. falciparum, P. vivax, and mixed in-
fections, respectively. Thrombocytopenia (platelet counts
<150,000 mm3) was present in 31.39% (86/274), 41.18%
(91/221), and 54.55% (24/44) adults having P. falciparum,
P. vivax, and mixed infections, respectively. Statistically,
it was significantly more common in mixed malaria
(p<0.004) and P. vivax malaria in comparison to P.
falciparum malaria (p<0.03). Four patients had ARDS
(two each caused by P. falciparum and P. vivax).
Thus, the observation of this study was that severe P.
vivax malaria cases have presented with similar pheno-
typic features to the P. falciparum malaria cases except
more cases of thrombocytopenia (p=0.03). In the patients
of mixed infections severe malaria also shared the same
phenotypic features of severe P. vivax or severe P.
falciparum monoinfection but the course of illness was
more serious, having more patients of multiorgan dys-
function (MODS) and increased mortality in comparison
to P. vivax or P. falciparum monoinfection. Similar ob-
servation was also reported by the only other study from
Papua New Guinea in which the diagnosis of malaria was
confirmed by PCR17.
During the past few years, reports from Indonesia,
Papua New Guinea, India, and the Amazon region de-
scribing severe and sometimes fatal disease in P. vivax
monoinfection have become more frequent. In spite of
low level of parasitaemia, the risk approximates those in
patients with a primary diagnosis of P. falciparum ma-
laria with heavy parasite burden. In a classical review,
Baird39 have provided detailed information of different
studies providing enough evidence of morbidity and mor-
tality associates with P. vivax malaria. The first detailed
study on severe vivax malaria was reported from Bikaner,
India describing 11 adult patients, with strong evidence
of both sequestration and non-sequestration related com-
plication. Jaundice, ARDS, severe anaemia and renal fail-
ure were present in four patients, cerebral malaria and
bleeding manifestation in three patients, and shock in two
patients. Eight patients had MODS and there was also
evidence of pregnancy related complication in the form
of premature delivery and death of baby. One patient had
post-malaria neurological syndrome (PMNS) in the form
of psychosis and death was reported in two patients6. Sub-
sequently in 2009, the authors reported 40 more adult cases
from the same institution describing similar clinical pre-
sentation and MODS12. Subsequently in 2010, the au-
thors reported 65 cases of severe P.vivax malaria in chil-
dren and observed that P. vivax had more patients of severe
anaemia and MODS in comparison to P. falciparum and
the case fatality rate was almost equal to severe P.
falciparum malaria (39 from P. vivax and 32 from P.
falciparum)14. The important observation from Bikaner
region, India was the common evidence of jaundice and
renal failure in adults whereas severe anaemia and cere-
bral malaria were more common in children group6,12,14.
The only other PCR diagnosed study from central India
on 22 cases also reported evidence of cerebral malaria,
anaemia, seizure, ARDS and MODS. PMNS was observed
in two patients and death was recorded in two patients28.
The study from Brazil on 17 patients revealed almost
similar observation. Ten patients had jaundice, five had
anaemia, two each ARDS and renal failure, one each of
shock and hemoglobinuria. Fifteen patients had thromb-
ocytopenia. MODS was present in four patients and death
was reported in one patient13. Another study on 19 pa-
tients from Brazil revealed the presence of jaundice in
seven patients, ARDS in six patients, MODS in four pa-
tients and death was reported in six patients19. The study
from Papua New Guinea children on 27 patients of se-
vere vivax malaria revealed eight patients of respiratory
distress, seven patients of convulsion, six patients of ce-
rebral malaria, five patients of metabolic acidosis/hyper
lactatemia, three patients of severe anaemia, two patients
of hypoglycemia, and one patient of renal impairment.
Jaundice was not present in any patient. Presentation of
severe P. vivax malaria was similar to severe P. falciparum
malaria except five times more cases of respiratory dis-
tress associated with P. vivax monoinfection. They also
reported death in one child17. It is quite apparent from
these studies that India and Brazil have almost similar
clinical presentation in the form of increased incidence
of jaundice, renal failure and thrombocytopenia along with
MODS, whereas in Papua New Guinea the common pre- 207 Kochar  et al: Severe vivax and mixed infection malaria
sentation is cerebral malaria, metabolic acidosis, respira-
tory distress and severe anaemia.
There are two studies related to detailed description
of cerebral malaria in P. vivax monoinfection. The Indian
study describes 13 patients of cerebral malaria (2–13 yr)
with one death. Eight children had MODS and there was
no evidence of neurological sequelae18. In an another
study from Papua, Indonesia on six adults (16–25 yr),
one patient had tremors and myoclonus as a PMNS and
there was no death16. PMNS has also been reported in
other Indian studies in the form of bilateral facial palsy,
psychosis and tremors6,8,28.
There are two retrospective studies from Pakistan in
which PCR was done only in few patients and thus the
results cannot be compared with other studies. However,
the most important complications were cerebral malaria
followed by severe thrombocytopenia, severe anaemia and
MODS, and death was reported in one patient. The clini-
cal presentation of severe P. vivax monoinfection was
similar to severe P. falciparum monoinfection in both the
studies23,27.
The reports on thrombocytopenia with severe malaria
in PCR diagnosed patients of P. vivax malaria are very few.
In a study by Kochar et al15, on 1064 adult patients, the
authors reported severe thrombocytopenia (<20,000) in 39
patients (26 P. falciparum, 9 P. vivax and 4 mixed infec-
tions). They reported that the association of thrombocytope-
nia was statistically more significant with P. vivax
monoinfection as compared to P. falciparum
monoinfection. Six patients (3 P. vivax, 2 P. falciparum and
1 mixed) had severe epistaxis and required platelet trans-
fusion for management15. In a similar study on 676 chil-
dren, the authors observed that the association of other
severe manifestations was significantly more common in
children having P. vivax monoinfection with severe throm-
bocytopenia. Severe thrombocytopenia was present in 73
patients and bleeding manifestation was present in 63 pa-
tients21. Thrombocytopenia was also reported in 15 out of
17 patients in a Brazilian study on severe vivax malaria13.
Thus, regardless of how this parasite is pernicious,
the available data demonstrated that the infections come
as a significant burden of morbidity and associated with
mortality39. In spite of definite evidence of severe P. vivax
malaria on PCR diagnosed patients from different regions
of the world and well supported by autopsy report from
India and Brazil32–33, more detailed prospective, clinico-
epidemiological studies are needed to establish whether
the increased reports of severe vivax malaria in the past
five years are a result of multifocal emergence of virulent
strains, previously underestimated severity, or over-re-
porting30.
The clinical research on the impact of mixed infec-
tion on human health is still controversial, while some
workers believe it to be a beneficial situation whereas
others consider it to be detrimental7,11,34–37. The vast dif-
ference in results may be due to large scale incorrect spe-
cies diagnosis by PBF, attributed to various factors. Pre-
vious studies on severe malaria with more number of
cases10–11 have strongly pointed about the limitation of
their study with a note of concern that mixed infections
might have been largely underestimated and the use of a
more sensitive diagnostic method might have had differ-
ent results.
The magnitude of wrong diagnosis by PBF is evident
through a study by Lamph et al16 in which out of 24 pa-
tients of PBF diagnosed P. vivax monoinfection patients
of coma, the PCR was positive for mixed infection in 10
patients. Whereas, in an another study on 180 PBF diag-
nosed patients of monoinfection [P. falciparum 37
(20.5%), P. vivax 143 (79.5%) and mixed infection (0)],
the cross checking by PCR revealed mixed infection in
82 samples (45.5%), P. vivax in 85 (47.2%) and P.
falciparum in 13 (7.77%)40. In a similar study from Papua
New Guinea, the authors recorded only 16% concordance
with PBF (68% diagnosed as P. falciparum and 16% di-
agnosed as P. vivax on microscopy)17. Thus, the PCR has
a great role in the confirmation of mixed infection and
might be an important factor for differences in results of
various studies from different parts of the world
and thereby making them uncomparable. Accurate iden-
tification of the malaria parasite species is important not
only for successful treatment, but also to design and
develop effective malaria control measures and accurate
malaria-epidemiological monitoring. Since, there is
only one clinical study which describes difference
between clinical presentation, morbidity and mortality
pattern of mixed infection vs P. falciparum and P.
vivax monoinfection severe malaria, in which the
diagnosis was confirmed by PCR, the present hospital
based study using PCR for species diagnosis have spe-
cific relevance.
This study revealed that mixed infection severe ma-
laria patients had almost similar clinical and laboratory
findings to those of severe P. falciparum and P. vivax
monoinfection malaria (Table 1). However, their subse-
quent clinical progression to severe illness including
MODS and mortality was the highest of the three groups,
in spite of the fact that the observations were statistically
nonsignificant. Similar observations have also been re-
ported from the only other PCR confirmed study on mixed
infection severe malaria in children from Papua New
Guinea17. Since, all other studies have used PBF for spe- J Vector Borne Dis 51, September 2014 208
cies diagnosis, the data cannot be compared because of
species diagnosis dilemma.
In the present study, although 47.47% of multiorgan
dysfunction was caused by P. falciparum malaria, the risk
was greatest in patients having mixed infection in com-
parison to either P. falciparum monoinfection or P. vivax
monoinfection. Potentiality of P. vivax malaria for caus-
ing multiorgan dysfunction was similar to P. falciparum
malaria and similar observations were also recorded in
previous studies6,12–14,19. The mortality was reported in
34 patients (20 P. falciparum; 10 P. vivax; and 4 mixed)
and it was highest in the patients of mixed infection se-
vere malaria. The deaths reported in all the patients in
this series had severe manifestations and multiorgan dys-
function (Table 3). While analyzing the individual severe
manifestation, it was found that jaundice was the major
pernicious syndrome (85.29%) followed by severe
anaemia (52.94%), renal failure (47.05%), thrombocy-
topenia (41.18%) and cerebral malaria (20.59%) and there
was no statistical difference in different clinical and para-
sitological settings.
Exact pathogenesis and organ-specific morbidity
caused by P. vivax infection remains unrecognized and
poorly studied because of a paucity of research in this
area. Cytokine production, endothelial activation and
pulmonary inflammatory responses are higher during and
after P. vivax infections than in P. falciparum infections
of similar parasite biomass. Since, all stages of P. vivax
are visible in peripheral blood, albeit with partial deple-
tion of mature stages, sequestration is not thought to oc-
cur in a significant degree in P. vivax malaria or cause
end-organ dysfunction in the same manner as P.
falciparum. Recent in vitro data showed that P. vivax-
infected RBCs do cytoadhere to endothelial cells, via
ICAM-1 and chondroitin sulphate-A (CSA), with a simi-
lar strength but a 10-fold lower frequency than P.
falciparum-infected RBCs. Another study confirms
cytoadherence to the glycosaminoglycans, CSA and hy-
aluronic acid. The autopsy findings suggest that the sig-
nificant microvascular obstruction from sequestration of
parasitized red cells does not appear to occur in vivax
malaria, though it is possible that in some circumstances,
more limited cytoadherence to endothelial cells may oc-
cur, and may amplify local inflammatory responses in
affected organs, such as the lung or placenta. Rosetting,
adherence of non-infected to infected RBCs, has been
linked to the pathophysiology of severe P. falciparum
malaria. Rosetting has been described ex vivo in vivax
malaria; however, its role in P. vivax pathophysiology is
unknown. The pathophysiology of individual syndrome
had been critically reviewed by Anstey et al41. Recently,
in an editorial by Baird42 had rightly commented that in
spite of fact that there is no firm evidence of pathogen-
esis of severe vivax malaria, there is enough evidence of
its reality and its acceptance must not await demonstra-
tion of mechanism or cofactors. We have to acknowledge
real consequences without regard to their specific gen-
esis.
The strengths of the present study is its prospective
hospital based clinical observation study, the use of PCR
for diagnosis thereby negating any chances of species
misdiagnosis and scientific approach using thorough clini-
cal, bacteriological, radiological and other relevant stud-
ies to rule out possibilities of other comorbid condition.
Such a rigorous approach has been used in only few stud-
ies of severe malaria earlier. Thus, if we analyse the two
important epidemiological and clinical issues faced by
malariologists since the beginning of this century, our study
has some important observations to mention. This study
on severe malaria from an area of intense transmission of
multiple Plasmodium species has identified almost simi-
lar phenotype of P. vivax and P. falciparum monoinfection
as well as mixed infection in Bikaner, India. Multiorgan
dysfunction was also observed in all three situations. Simi-
lar observations have also been reported from other parts
of the world in PCR diagnosed patients of severe P.vivax
malaria and have also been supported by postmortem
examination. The second clinical dilemma regarding se-
vere malaria associated with mixed infection was also
having similar phenotype presentation with more chances
of developing severe illness, more severe clinical course
including increased incidence of MODS along with higher
rates of mortality and morbidity in comparison to P.
falciparum and P. vivax monoinfection severe malaria.
However, these observations were statistically not
significant presumably because of smaller sample size.
This important limitation requires a similar multicentric
clinico-epidemiological study on a larger population be-
fore a general statement can be made firmly. This obser-
vation is also supported by the only other PCR based study
from PNG. These findings provide a strong impetus for
further research on the pathogenic potential of P. vivax
monoinfection as well as P. falciparum/P. vivax mixed
infections. A further large-scale study involving differ-
ent countries is required to unearth the underlining patho-
genesis and its relation to multidrug resistance. The knowl-
edge of mixed infection is equally important for control
measures as well as therapeutic options and future vac-
cine programme. Thus, every effort to reduce or elimi-
nate malaria burden must also target P. vivax and mixed
infection along with P. falciparum in regions where both
these species coexist. 209 Kochar  et al: Severe vivax and mixed infection malaria
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